Non-Invasive Prenatal Testing (NIPT) with Source BioScience
Source BioScience provides an NIPT Service, enabling you to offer your patients a safe, non-invasive and simple solution to prenatal screening
What is NIPT?
Requiring only a small maternal blood sample, non-invasive prenatal testing uses cutting-edge technology to analyse foetal cell-free DNA (cfDNA) for chromosomal abnormalities.
We use the verifi® prenatal test, which can be performed as early as 10 weeks gestation.
What exactly can NIPT screen for?
Our NIPT Service screens for the following conditions in both singleton and twin pregnancies:
• Trisomy 21 (Down syndrome)
• Trisomy 18 (Edwards syndrome)
• Trisomy 13 (Patau syndrome)
In addition to the above, we can also screen for:
• Sex chromosome conditions (monosomy X, XXX, XXY, XYY)
• Other clinically significant trisomies (Please contact us for more information)
• The presence of a Y chromosome
Who can have the verifi® Prenatal Test?
You may wish to offer this screening test to pregnant women (at least 10 weeks gestation), who meet one or more of the following criteria:
• They are of advanced maternal age
• They have had an ultrasound revealing concerns or abnormalities with foetal growth and/or development
• They have had an abnormal/“positive” serum screen
• They have a personal/family history of chromosomal aneuploidies trisomies 21, 18 and 13, or sex chromosome aneuploidies
Why should I offer my patients NIPT?
Invasive procedures (like amniocentesis and chorionic villus sampling) carry a risk of miscarriage, whereas non-invasive prenatal testing is risk-free and can be performed as early as 10 weeks gestation.
NIPT provides your patients with an additional choice in the prenatal screening process. Combined with ultrasound/serum findings, your patients can use the NIPT result to decide whether or not to undergo an invasive procedure.
How are the test results reported?
The verifi® prenatal test has three possible results for the autosomes:
• Aneuploidy Detected
• Aneuploidy Suspected
• No Aneuploidy Detected
And for the sex chromosome analysis in singletons, there are two possible results:
• Aneuploidy Detected
• Aneuploidy Not Detected
In the case of sex chromosome analysis, where no aneuploidy is detected, foetal sex is reported for singleton pregnancies and the presence or absence of Y is reported for twin pregnancies.
It is important to note that this test is used for screening purposes only. As such, we recommend that all “Aneuploidy Suspected” and “Aneuploidy Detected” cases be followed up with genetic counselling and either an amniocentesis or CVS procedure.
Why do Source BioScience use the verifi® Prenatal Test?
For all NIPTs, the success of the test is dependent on the detection of foetal cell-free DNA in the maternal blood sample.
While there are several NIPTs available, the verifi® prenatal test is the most sensitive, and has the lowest redraw rate on the market (0.1%).
This means, only one in one thousand of your patients should have to be re-tested.
How does the Source BioScience NIPT Service work?
1) We supply your clinic with our NIPT kit, which has a test request form and the consumables required to perform a blood draw
2) You send us a blood sample and the test request form - in the freepost box provided
3) We analyse the sample and send you a report
For more information on our NIPT Service, contact us today.